Gout

This study is currently active

Northern California research is looking for participants who have a diagnosis of gout to participate in our new study. Participants must be ages 18-85 and taking medication to prevent gout flare ups. We are conducting a study for a new medication that would be taken in combination with your current medication to help control your uric acid levels.

This study is 2 years long and includes 14 office visits. All trial-related visits, tests, and medications will be provided to you at no cost. In addition, reimbursement for trial-related time and travel may be provided. Please fill out the survey and we will be contacting you to provide study specific information.

This study evaluates the safety and efficacy of lesinurad administered with an XOI versus a placebo plus an XOI in gout participants who have moderate renal impairment and who are not at target level of sUA.
This postmarketing study is a randomized, double-blind, placebo-controlled study to evaluate safety (with particular focus on renal and cardiovascular events) and efficacy of lesinurad 200 mg QD in combination with an XOI for up to 24 months compared with XOI monotherapy, in participants with gout and moderate renal impairment who have not reached target sUA levels (<6.0 mg/dL) on an XOI alone.
Inclusion Criteria:
  1. Subject is 18 – 85 years of age with diagnosis of gout and BMI <45.
  2. Subject has moderate renal impairment
  3. Subject has been taking an XOI as urate-lowering therapy (ULT) indicated for the treatment of gout.
  4. Subject is male or female; females must not be pregnant or breastfeeding and females of childbearing potential must agree to use non hormonal contraception during the Screening Period and while taking investigation product (IP).

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03226899

Participate in a Study

Submit the form and a clinical study expert will get in touch with you.

Want to know more about our clinical trials?